文献速递呼吸危重症与机械通气呼吸道感染

重症COVID-19肺移植的早期结局:四国首批连续病例系列

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries.
PubMed 文献 · Lancet Respir Med · 2021-03-31

该多中心病例系列报告了2020年5月1日至9月30日在美国、意大利、奥地利和印度6个中心接受双肺移植的12例COVID-19相关ARDS患者。移植前影像显示严重肺损伤,虽经长时间机械通气和体外膜氧合仍未改善;手术技术困难,病理示持续急性肺损伤伴纤维化特征,移植物无SARS-CoV-2复发,所有患者均脱离体外支持,短期生存与无COVID-19的移植受者相似。

要点

  • 重症COVID-19相关ARDS肺康复无望且濒临死亡者,肺移植可作为挽救生命的选项
  • 移植肺未出现SARS-CoV-2复发,短期生存与无COVID-19受者相似
  • 此类手术技术挑战大,需严格选择患者并在高容量中心实施

核心结论

  • 对部分严重且不可逆的COVID-19相关ARDS患者,肺移植是唯一生存选择,在严格选择患者中可成功实施并获良好早期结局。

研究设计与样本

  • 多机构病例系列,纳入美国、意大利、奥地利和印度已知首批连续因重症COVID-19相关ARDS接受肺移植的病例,由西北大学收集并分析去标识化数据。
  • 2020年5月1日至9月30日,12例患者在6个高容量移植中心接受双肺移植:美国8例(3个中心)、意大利2例(1个中心)、奥地利1例、印度1例。

主要发现

  • 受者中位年龄48岁(IQR 41-51),12例中3例为女性。
  • 移植前胸部影像显示严重肺损伤,尽管长时间机械通气和体外膜氧合仍未改善。
  • 移植手术技术困难,存在严重胸膜粘连、肺门淋巴结肿大和术中输血需求增加。
  • 切除肺病理显示广泛、持续的急性肺损伤伴肺纤维化特征。
  • 移植肺无SARS-CoV-2复发;所有COVID-19患者均脱离体外支持,短期生存与无COVID-19的移植受者相似。

临床怎么用

  • 对优化内科治疗后肺功能无恢复且因肺部并发症濒临死亡的COVID-19相关ARDS患者,可考虑肺移植。
  • 实施需在高容量移植中心,认识严重胸膜粘连等技术挑战并做好术中输血准备。
  • 移植后需关注原发疾病病理特征及移植物SARS-CoV-2复发情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung transplantation is a life-saving treatment for patients with end-stage lung disease; however, it is infrequently considered for patients with acute respiratory distress syndrome (ARDS) attributable to infectious causes. We aimed to describe the course of disease and early post-transplantation outcomes in critically ill patients with COVID-19 who failed to show lung recovery despite optimal medical management and were deemed to be at imminent risk of dying due to pulmonary complications. METHODS: We established a multi-institutional case series that included the first consecutive transplants for severe COVID-19-associated ARDS known to us in the USA, Italy, Austria, and India. De-identified data from participating centres-including information relating to patient demographics and pre-COVID-19 characteristics, pretransplantation disease course, perioperative challenges, pathology of explanted lungs, and post-transplantation outcomes-were collected by Northwestern University (Chicago, IL, USA) and analysed. FINDINGS: Between May 1 and Sept 30, 2020, 12 patients with COVID-19-associated ARDS underwent bilateral lung transplantation at six high-volume transplant centres in the USA (eight recipients at three centres), Italy (two recipients at one centre), Austria (one recipient), and India (one recipient). The median age of recipients was 48 years (IQR 41-51); three of the 12 patients were female. Chest imaging before transplantation showed severe lung damage that did not improve despite prolonged mechanical ventilation and extracorporeal membrane oxygenation. The lung transplant procedure was technically challenging, with severe pleural adhesions, hilar lymphadenopathy, and increased intraoperative transfusion requirements. Pathology of the explanted lungs showed extensive, ongoing acute lung injury with features of lung fibrosis. There was no recurrence of SARS-CoV-2 in the allografts. All patients with COVID-19 could be weaned off extracorporeal support and showed short-term survival similar to that of transplant recipients without COVID-19. INTERPRETATION: The findings from our report show that lung transplantation is the only option for survival in some patients with severe, unresolving COVID-19-associated ARDS, and that the procedure can be done successfully, with good early post-transplantation outcomes, in carefully selected patients. FUNDING: National Institutes of Health. VIDEO ABSTRACT.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Bharat A, Machuca TN, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med. 2021. PMID: 33811829. doi:10.1016/S2213-2600(21)00077-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。